AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis
AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis |!| Mount Carmel
